by IonsGate Preclinical Services | Aug 16, 2019 | Research
Cellular models developed to better predict proarrhythmic liability of drug candidates include commercially-available human stem cell-derived cardiomyocytes (hiPSC-CM) obtained from healthy subjects. Cardiac safety assessment, however, should not be limited to...
by IonsGate Preclinical Services | Feb 7, 2019 | Research
Cellular models developed to better predict proarrhythmic liability of drug candidates include commercially-available human stem cell-derived cardiomyocytes (hiPSC-CM) obtained from healthy subjects. Cardiac safety assessment, however, should not be limited to...
by IonsGate Preclinical Services | Oct 6, 2016 | Research
If you missed Dr Pourrier’s presentation on the late sodium current (late INa) at the last SPS meeting in Vancouver (18-21 September 2016), you can download it here: Your Name (required) Your Email (required) [recaptcha]...
by IonsGate Preclinical Services | Nov 19, 2015 | Assays
Purkinje fiber assay It is well appreciated that acquired or drug induced-torsade de pointes (TdP), is associated with the generation of long action potential duration (APD)-related early after depolarizations (EADs) and EAD-induced triggered activity. EADs, occurring...
by IonsGate Preclinical Services | Nov 19, 2015 | Preclinical
hERG is only really the beginning…CiPA is coming Current practice in cardiac safety pharmacology has been successful in preventing proarrhythmia- related post approval drug withdrawal. However, many challenges remain in the assessment of cardiac effects of new drugs....
